Cargando…

Efficacy and Safety of Investigational Microbiome Drug SER-109 for Treatment of Recurrent Clostridioides difficile Infection

Background: Antibiotics targeted against Clostridioides difficile bacteria are necessary, but insufficient, to achieve a durable clinical response because they have no effect on C. difficile spores that germinate within a disrupted microbiome. ECOSPOR-III evaluated SER-109, an investigational, biolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGovern, Barbara, Sims, Mathew, Kraft, Colleen, Wang, Elaine, Brady, Kelly, Ford, Christopher, Edward, O’Brien, Lombardo, Mary-Jane, Wortman, Jennifer, Litcofsky, Kevin, Mahoney, Jennifer, McChalicher, Christopher, Winkler, Jonathan, Garant, Sarah, Aunins, John, Henn, Matthew, von Moltke, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	C. difficile
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551515/ http://dx.doi.org/10.1017/ash.2021.10

Ejemplares similares

Healthcare resource utilization in a phase 3 trial of SER-109 in patients with recurrent Clostridioides difficile infection
por: Cohen, Stuart, et al.
Publicado: (2022)

Integrated efficacy analysis from phase 3 studies of investigational microbiome therapeutic, SER-109, in recurrent Clostridioides difficile infection
por: Sims, Matthew, et al.
Publicado: (2023)

Integrated safety analysis of phase 3 studies for investigational microbiome therapeutic, SER-109, in recurrent CDI
por: Sims, Matthew, et al.
Publicado: (2023)

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial
por: McGovern, Barbara H, et al.
Publicado: (2020)

Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
por: McChalicher, Christopher, et al.
Publicado: (2022)

Clostridioides difficile: A diagnostic intervention
por: Alsoubani, Majd, et al.
Publicado: (2022)

Examining the impact of the COVID-19 pandemic on hospital-associated Clostridioides difficile infection
por: Ray, Michael, et al.
Publicado: (2023)

Role of diagnostic stewardship in reducing healthcare facility-onset Clostridioides difficile infections
por: Shallal, Anita, et al.
Publicado: (2022)

Clostridioides difficile Is Not Difficult to Predict in Hospital Settings
por: Alexander, Kinta, et al.
Publicado: (2021)

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

1035. Manufacturing Processes of SER-109, a Purified Investigational Microbiome Therapeutic, Reduce Risk of Transmission of Emerging and Undetected Infections in Donor Stool
por: McChalicher, Christopher, et al.
Publicado: (2021)

Clinical Characteristics and Fecal Microbiome in Recurrent Versus Nonrecurrent Clostridioides difficile Infection
por: Lanjewar, Swapnil, et al.
Publicado: (2021)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

Evaluation of the genomic epidemiology and transmission of Clostridioides difficile infection across a community
por: Tesini, Brenda, et al.
Publicado: (2022)

Did Clostridioides difficile Testing and Infection Rates Change During the COVID-19 Pandemic?
por: Hawes, Armani, et al.
Publicado: (2021)

Clostridioides difficile infection (CDI) treatment outcomes and recurrence factor at a pediatric hospital
por: Tran, Martin Tuan, et al.
Publicado: (2022)

Prospective audit and feedback of Clostridioides difficile PCR at the time of ordering increases appropriateness of testing
por: Tassone, Daniel, et al.
Publicado: (2022)

Characteristics of antibiotic exposures for surgical procedures prior to Clostridioides difficile diagnosis—Minnesota, 2018
por: D’Heilly, Paige, et al.
Publicado: (2022)

Impact of Two-Step Testing Algorithm on Reducing Hospital-Onset Clostridioides difficile Infections
por: Navalkele, Bhagyashri, et al.
Publicado: (2021)

Impact of early identification of patients meeting testing criteria for Clostridioides difficile on standard infection ratios
por: Krier, Brad, et al.
Publicado: (2023)

1641. Treatment of Recurrent Clostridium difficile Infection With SER-109 Reduces Gastrointestinal Carriage of Antimicrobial Resistance Genes
por: Ford, Christopher, et al.
Publicado: (2018)

655. Analysis of Microbiome Diversity and Secondary Bile Acid Synthesis Following SER-109 or Placebo in Patients with First Recurrent or Multiply Recurrent Clostridioides difficile Infection
por: Kelly, Colleen R, et al.
Publicado: (2023)

SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI)
por: Khanna, Sahil, et al.
Publicado: (2022)

621. Treatment of Recurrent Clostridium difficile Infection with SER-109 Increases the Concentration of Secondary Bile Acids in a Dose-Dependent Manner
por: Henn, Matthew, et al.
Publicado: (2018)

In veteran outpatients, antibiotics remain significant risk factor for community-acquired Clostridiodes difficile infection
por: Akpoji, Ukwen, et al.
Publicado: (2022)

Impact of exposure to potentially contaminated hospital beds on risk of hospital-onset C. difficile infection
por: Witt, Lucy, et al.
Publicado: (2022)

Effects of a hard stop for C. difficile testing: Provider uptake and patient outcomes
por: Doughman, Danielle, et al.
Publicado: (2023)

653. Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI)
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)
por: Henn, Matthew, et al.
Publicado: (2017)

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial
por: Sims, Matthew D., et al.
Publicado: (2023)

Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool
por: McChalicher, Christopher W J, et al.
Publicado: (2023)

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial
por: Garey, Kevin W., et al.
Publicado: (2023)

Did Clostridioides difficile testing and infection rates change during the COVID-19 pandemic?
por: Hawes, Armani Minasian, et al.
Publicado: (2021)

Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile
por: Huhulescu, Steliana, et al.
Publicado: (2011)

Infection of hamsters with the UK Clostridium difficile ribotype 027 outbreak strain R20291
por: Buckley, Anthony M., et al.
Publicado: (2011)

A cortex-specific penicillin-binding protein contributes to heat resistance in Clostridioides difficile spores
por: Alabdali, Yasir Adil Jabbar, et al.
Publicado: (2021)

Clostridioides difficile infection: curbing a difficult menace
por: Khanna, Sahil, et al.
Publicado: (2022)

Immune response against Clostridioides difficile and translation to therapy
por: Sehgal, Kanika, et al.
Publicado: (2021)

Epidemiology of community-acquired and recurrent Clostridioides difficile infection
por: Fu, Yichun, et al.
Publicado: (2021)

The interplay of Clostridioides difficile infection and inflammatory bowel disease
por: Sehgal, Kanika, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e0tvma2fnn5e1ml1hj3ev9ka8o